ANTI-CANCER PROTEOLYTIC ANTIBODIES

Information

• Research Project
• 6779630

• ApplicationId

  6779630

• Core Project Number

  R43CA107603

• Full Project Number

  1R43CA107603-01

• Serial Number

  107603

• FOA Number

  PAR-03-074

• Sub Project Id

• Project Start Date

  4/1/2004 - 20 years ago

• Project End Date

  3/31/2005 - 19 years ago

• Program Officer Name

  MUSZYNSKI, KAREN

• Budget Start Date

  4/1/2004 - 20 years ago

• Budget End Date

  3/31/2005 - 19 years ago

• Fiscal Year

  2004

• Support Year

  1

• Suffix

• Award Notice Date

  3/15/2004 - 20 years ago

Organizations

• Integrigen, Inc.

[unreadable] DESCRIPTION (provided by applicant): Antibody therapy is now common for several diseases. Some unique antibodies contain a protease function, with the ability to specifically degrade their target antigen. IntegriGen has cloned unique proteolytic antibody genes and will engineer them to bind and cleave therapeutically relevant target antigens. This project has three specific aims: 1) Clone and engineer libraries of proteolytic antibodies, 2) synthesize fluorophosphonate probes capable of specifically binding active proteases, and 3) screen the libraries of aim (1) against the model tumor antigen VEGF and the fluorophosphonate probe of aim (2) to discover new antigen specific proteolytic antibodies. [unreadable] [unreadable] [unreadable]

IC Name

• Activity

  R43

• Administering IC

  CA

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  100000

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  395

• Ed Inst. Type

• Funding ICs

  NCI:100000\

• Funding Mechanism

• Study Section

  ZCA1

• Study Section Name

  Special Emphasis Panel

• Organization Name

  INTEGRIGEN, INC.

• Organization Department

• Organization DUNS

• Organization City

  NOVATO

• Organization State

  CA

• Organization Country

  UNITED STATES

• Organization Zip Code

  94949

• Organization District

  UNITED STATES